News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Karolinska Development AB: Pergamum Announces Last Visit of Last Patient in a Phase I/II Trial of a Potential New Treatment for Hard-to-Heal Wounds


4/19/2013 11:24:23 AM

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Karolinska Development AB (STO:KDEV):

Pergamum AB announced today that the company has reached last-patient-last-visit (LPLV) in a randomized Phase I/II trial of LL-37 for the treatment of hard-to-heal venous leg ulcers. Karolinska Development AB is the majority owner of Pergamum.

Non-healing wounds are a sizable burden for the individual patient and for the health care system. Today, there are more than 15 million patients globally, and virtually no medical progress has been made over the last few decades in regard to pharmacological treatments.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES